Obermatt
See Similar Stocks →

Aktis Oncology

NSQ:AKTS · US01021M1045
BiotechnologyX-Small

360

28
Medium confidence — indicative
Profit price78
Owner Earnings Yield1
Dividend Yield1
Price/Sales40
Price/Book67
Returns on capital73
Profit margins26
Cash backing9
Sales growth73
Profit Growth62
Long-Term EPS Growth71
Reinvestment14
Price momentum12
Debt load71
Refinancing34
Debt Payback1
Liquidity1
Analyst ratings73
Opinion Changes50
Price Target Upside37
Market mood1

Profile

CountryUSA
IndustryBiotechnology
SizeX-Small
TypePublic Company
ExchangeNASDAQGS
Founded2020
Employees80
Websiteaktisoncology.com
ISINUS01021M1045
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OncologyUrologyBiotechnologyScience and Engineering

Description

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company has…

Analysis

Middle-of-the-road

Aktis Oncology, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
37
2023202420252026

All-time high

86

Mar 2026

All-time low

12

Jan 2025

Average rank

53

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
40
100
65
25
Price/Earnings
73
24
24
24
Price/Book
67
96
92
64
Dividend Yield
1
1
1
1
Value (overall)
90
87
61
41

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Aktis Oncology with its peers
Elicio Therapeutics
NAQ:ELTX
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Anixa Biosciences
NAQ:ANIX
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Cogent Biosciences
NSQ:COGT
54
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Revolution Medicines
NSQ:RVMD
32
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Stoke Therapeutics
NSQ:STOK
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →